Background: De-escalation of bone-targeted agents, such as bisphosphonates and denosumab, from 4-to 12-weekly dosing is an increasingly used strategy in patients with bone metastases from breast cancer. It is unclear whether there is sufficient evidence to support de-escalation as a standard of care.
in addition to reducing costs to both the patient and the health care system. A previous systematic review showed that a number of studies have explored de-escalation of bone-targeted agents [18] . As there is now more data available, a systematic review and meta-analysis was carried out in order to assess whether or not de-escalation should be considered standard of care in patients with bone metastases from breast cancer.
methods research question and eligibility criteria
The literature search of an existing systematic review covering publications between 1946 to February 2013 [18, 19] . Additional data have been presented since that time and, therefore, the current systematic review extended the coverage of the literature search from March 2013 until November 2014. The research question was phrased in the Population-Intervention-ComparatorOutcomes-Study design framework as: 'Does administration of bone-targeted agents every 12 weeks, to breast cancer patients with bone metastases, provide similar benefit and fewer harms compared with 3-4 weekly (Q3-4w) administration?' Studies were eligible if they were randomized, included patients with breast cancer, and involved treatment with any bone-targeted agent. No additional criteria related to duration and dose of bone-targeting agent used before study enrolment was specified. The clinical outcomes of interest were SREs, bone pain (measured by a validated scale), quality of life (measured by a validated scale), adverse events (AEs; renal outcomes, osteonecrosis of the jaw (ONJ), bone pain, hypocalcaemia) and reduction in bone turnover biomarkers [urinary N-terminal telopeptide (NTx), serum C-terminal telopeptide (CTx)]. The comparator was standard 3-4 weekly treatment with the same bone-targeted agent as in the de-escalated arm.
literature search to identify studies An electronic literature search was designed for our original review [18] by an information specialist to identify potentially eligible citations from: Ovid Medline (-present), PubMed (for nonMedline records) and Cochrane Register of Controlled Trials. The search was peer-reviewed by a second librarian according to PRESS criteria [20] . The search strategy for Ovid Medline(R) is provided in supplementary Appendix S1, available at Annals of Oncology online. Conference abstracts for three major oncology meetings (American Society of Clinical Oncology, European Society for Medical Oncology and San Antonio Breast Cancer Symposium) from 2013 to 2014 were also searched (supplementary Appendix S2, available at Annals of Oncology online).
study selection
Stage 1 review consisted of screening of all titles and abstracts by two independent reviewers to identify a set of potentially relevant citations. Full-text articles of the citations identified in data collection and risk of bias assessment
Data collection was carried out by two reviewers using a standardized data collection form. This form gathered information from each study in terms of publication characteristics, patient eligibility criteria and demographics, intervention details (including type of bone-targeting agent used and frequency thereof) and outcome data as mentioned earlier. Studies were independently assessed for risk of bias by two reviewers (MFKI, CJ) using the Cochrane Collaboration's risk of bias tool for randomized trials [22] Discrepancies in data collection were resolved by discussion among the reviewers. When selected citations were not available as peer-reviewed manuscripts, the abstracts were used for data extraction (but were not assessed for risk of bias). Funding for the study was from internal sources, there was no pharmaceutical company funding.
data analysis
If studies were judged sufficiently homogeneous, in terms of patient characteristics and study design, we planned to use random-effects meta-analysis to synthesize outcome data. Continuous outcome measures were summarized as weighted mean differences while binary outcomes were synthesized using odds ratios, and all summary estimates were reported with point estimates and corresponding 95% confidence intervals (CIs). Findings were presented using forest plots which also included study-level effect estimates to enable inspection of variability in findings from study to study for each outcome. Statistical heterogeneity was assessed using the Cochrane Q statistic and the I 2 statistic [23] . The standard treatment arm (Q4w) was used as the reference treatment of all meta-analyses. Where data were not considered amenable to meta-analysis based on study characteristics, a narrative approach to summary of study-specific results was employed.
results
quantity of evidence identified
The electronic literature search identified 158 unique citations from March 2013 to November 2014 following removal of duplicate citations, and the five studies included in the 2013 review were also screened again. Stage 1 screening identified five potentially eligible new citations for full-text review along with the existing collection of studies. At stage 2 screening, all five of the new citations were found to meet the pre-specified eligibility criteria [15, [24] [25] [26] [27] , two of which were published as meeting abstracts (Hortobagyi's OPTIMIZE-2 study [25] and Templeton's REDUSE study [26] ). A total of five new trials consisting of 904 patients were included, in addition to four studies [28] [29] [30] from the previous review [18, 19] . One study [31] included in the [26] is ongoing with no available outcome data. Figure 1 shows an overview of the study selection process, while supplementary Appendix S4, available at Annals of Oncology online, lists included and excluded studies after full-text screening. A total of nine manuscripts, representing seven unique trials, were included. An overview of their characteristics is provided in Table 1 . Detailed narrative summaries of each of the included studies have is provided in supplementary Appendix S5, available at Annals of Oncology online.
study characteristics
Three studies (OPTIMIZE-2 [25] REDUSE [26] and BISMARK [30] ) selected for inclusion were available as abstracts with limited study data. Characteristics of the studies are described in Table 1 . One study was published in 2007 [30] , one in 2009 [15] , one in 2012 [30] , three in 2013 [24, 28, 29] and three in 2014 [25] [26] [27] . Among the studies, five were funded by industry [15, 25, 28, 30] , two were internally funded [24, 29] , one biomarker substudy was funded by a peer-reviewed grant [27] and one was funded by the national health insurance provider [26] . The number of enrolled patients ranged from 30 [27] to 425 [28] . The study durations varied between 13 weeks and 2 years [30] . Four studies were open labelled [15, [28] [29] [30] . One study was double blind for the denosumab arms [30] and one was initially double blind but subsequently unblinded to enhance accrual [25] . Three were pilot feasibility studies [24, 27, 29] . One study evaluated deescalation with pamidronate [29] , three with zoledronate [25, 28, 29] and two with denosumab [15, 30] .
Four full-text articles were available for risk of bias assessment [15, 28, 29, 30] (supplementary Appendix S6, available at Annals of Oncology online). Two studies were excluded from bias assessment as the study used the same randomized trial data as one of the included studies [24] . Two studies were excluded, as they were available in abstract form only [25, 30] . One study ([29] was judged to have high risk of bias in the domain blinding of outcome assessment, while one other [30] had high risk of bias in regard to blinding of participants and personnel.
patient characteristics
All studies enrolled patients with metastatic breast cancer with bone involvement, while another included patients with a range of malignancies [15] and one ongoing study also includes patients with prostate cancer [26] . For the study with mixed tumour types, as much breast cancer-specific data as possible was extracted from the corresponding manuscript (and subsequent update [32] and from www.clinicaltrials.gov). Prior treatment with bisphosphonates before randomization was an inclusion criterion in five studies [15, 24, 25, 28, 29] and an exclusion criterion in three [26, 30] .
findings skeletal-related events: Studies reported a number of SRErelated outcomes including SRE rates (proportion of patients experiencing at least one on study SRE) (six studies), time-to-first on-study SRE (one study) and skeletal morbidity rates (SMRs) (three studies). As there was available data for the number of patients experiencing on-study SREs available from five trials, metaanalysis of this outcome was carried out. Data for on-study SRE rates for both bisphosphonates and denosumab between standard (87/516 SREs) and de-escalated (88/510 SREs) arms produced a summary risk ratio (RR) of 0.90 (95% CI 0.63-1.29) (Figure 2 ). Statistical heterogeneity, as measured by I The number of patients experiencing an SRE in each intervention group is shown for each study, along with results from meta-analysis expressed as a risk ratio with 95% confidence interval. Studies are grouped according to the agent used. The control group is standard q-4w treatment with a bone targeting agent. bone-marker-directed therapy, respectively. The BISMARK study [30] was of a fundamentally different design to the other de-escalation studies, as the dosing interval was based on individual patient bone turnover biomarker levels. While BISMARK closed before reaching its primary end point, there was no statistically significant difference in the occurrence of SREs between the different intervention groups.
As with most studies of bone-targeted agents, radiotherapy to bone is the most frequently expected SRE. Three included studies reported the incidence of radiotherapy to bone. The REFORM study reported totals of 2/19 (11%) and 2/19 (11%) patients experiencing radiotherapy to bone, in the standard and de-escalated arms, respectively [29] . The ZOOM study reported radiotherapy rates of 24/216 (11%) and 22/209 (11%) for 4-and 12-weekly zoledronate arms, respectively [28] ; while BISMARK reported totals of 87 (60.8%) and 84 (57.5%), in the bonemarker-directed zoledronate and standard zoledronate arms, respectively [30] . OPTIMIZE-2 [25] also reported time-to-first on-study SRE (hazard ratio 1.06; 95% CI 0.70-1.60).
pain: Data using validated measures of bone pain were only available from two studies. The REFORM study reported data using The Brief Pain Inventory (BPI) and Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP) [24, 27, 29] . Trends in pain scores over time for both FACT-BP and BPI did not significantly differ between groups for cumulative scores from baseline to 48 weeks (P = 0.386). The ZOOM study reported that there was no difference between the standard and de-escalated groups in bone pain, as assessed by the Verbal Rating Score for pain on movement or pain at rest at the end of the study [26] . Given the variation in the reporting of pain outcomes, a metaanalysis was not carried out.
adverse events: A number of different AEs and toxicities were reported. As most studies used different methods of assessment their findings are presented in supplementary Appendix S5, available at Annals of Oncology online. For the purposes of metaanalysis, data for on-study renal AEs was available from five studies. Comparison of standard (23 events; 21 AEs and 2 SAEs) and de-escalated (20 events; 17 AEs and 3 SAEs) arms using meta-analysis produced a summary risk ratio of 0.86 (95% CI 0.48-1.53) ( Table 2 and supplementary Appendix S7a, available at Annals of Oncology online). Statistical heterogeneity as measured by I 2 was low (0%). For on-study ONJ, data were available from five studies; again, due to the fundamentally different design of the study, data from BISMARK were excluded from the meta-analysis. Comparison of standard (5 events; 2 AEs and 3 SAEs among 600 patients) and de-escalated (4 events, all SAEs among 551 patients) arms produced a summary risk ratio of 0.83 (95% CI 0.16-4.42) ( Table 2 and supplementary Appendix S7b, available at Annals of Oncology online). Statistical heterogeneity, as measured by I 2 was low (22%); it is noted that three of the five studies were excluded from meta-analysis due to the presence of 0 events in both groups.
Data for on-study bone pain, as an AE, were available from three studies. Comparison of standard (30 events) and deescalated (21 events) arms produced a summary risk ratio of 0.86 (95% CI 0.46-1.62) ( Table 2 and supplementary Appendix S7c, available at Annals of Oncology online). Statistical heterogeneity, as measured by I 2 , was low (0%). Finally, due to the Table 2 . biomarkers of bone turnover: Biomarkers of bone turnover such as CTx and NTx have been used in a number of studies as a surrogate marker for risk for mortality and subsequent SRE risk [33, 34] . Five trials reported data on bone turnover biomarkers (Table 3 and supplementary Appendix S7e-f, available at Annals of Oncology online). Individual study data are shown in supplementary Appendix S4, available at Annals of Oncology online. Meta-analysis of both uNTx (Table 3 and supplementary Appendix S7e, available at Annals of Oncology online) and sCTx (Table 3 and supplementary Appendix S7f, available at Annals of Oncology online) showed no statistically significant differences between the standard and de-escalated arms. Statistical heterogeneity, as measured by I 2 , was low for uNTx (0%) and sCTx (10%).
discussion
The increasing interest from oncologists [10] and patients [13] in identifying the optimal dosing interval of bone-targeting agents [9] has been driven mainly by concerns regarding the toxicity of these increasingly potent agents being used for increasingly periods of time [16] . However, if de-escalation of treatment to less frequent dosing is as efficacious as 3-4 weekly dosing, it could not only lessen clinic visits for patients, but could also lead to reduced drug side-effects and costs to both the patient and the health care system. SREs are the most commonly studied end point for trials of bone-targeting agents. SRE data were available from all included studies either in terms of time-to-first on-study SRE, percentage of patients having an on study SRE, or as the skeletal morbidity rate. The results of the meta-analysis for the number of patients having on study SREs showed no evidence of a difference between the de-escalated and standard arms, with an inconclusive CI and summary estimate near the null (RR 0.99, 95% CI 0.76-1.29). Similarly, another important palliative indication for bone-targeted agents is pain control. Unfortunately, while individual studies reported no difference between arms for pain scores, there were insufficient common data to allow for metaanalysis to be carried out.
Another potential benefit of de-escalation would be for reduction of the frequencies of AEs and toxicity. While the data from individual studies would suggest that standard dosing was associated with increased rates of renal toxicity [25] , osteonecrosis of the jaw [30] , GI symptoms [28] than de-escalated therapy (Table 2 and supplementary Appendix S7, available at Annals of Oncology online), the variable reporting for different studies in terms of the type of tool used for measuring each type of toxicity placed limitations on meta-analyses. However, it appears that overall, for renal toxicity, osteonecrosis of the jaw, bone pain and hypocalcaemia, there were no statistically significant differences between study arms.
Biomarkers of bone turnover have been used as a surrogate indicator for pain, survival and subsequent SRE risk [35, 36] . There were variations between the studies in terms of which biomarkers were collected, with studies using urinary NTX [13, 26] , sCTx [29, 30] or BSAP [30] . Only one study used all three markers [30] . As with the toxicity reporting, the different types of analysis used to define biomarker response placed limitations on metaanalyses. However, the role of biomarkers of bone turnover as a surrogate of subsequent SRE risk, in an era of increasingly effective anti-cancer therapies, is being increasingly questioned [34] .
There are a number of limitations to both the studies included in this review and the subsequent meta-analyses. Studies used different agents (pamidronate, zoledronate or denosumab), enrolled patients with different durations of prior bone-targeted agent use (either no prior therapy [26, 30] , >3 months [29] , >9 months [25] or 9-12 months [28] ), and did not always report common clinical end points. Important palliative outcomes including pain and use of analgesia were only available in two studies, and no studies reported on quality of life. Importantly, three studies were only available as meeting abstracts [25, 26, 30] ; given this limitation, additional details of interest in terms of study methods, patient flow and observed outcomes were not available, and we could not formally assess these studies for risk of bias. The OPTIMIZE-2 study had a change in trial methodology from double blind to unblinded after commencing as part of a successful attempt to increase accrual. Additionally, one study terminated early due to conclusions There is increasing interest from patients and physicians about the use of de-escalated bone-targeted therapy. In this systematic review of studies of bisphosphonates and denosumab, there appears to be no difference in SREs or pain with de-escalated therapy. While a large, hopefully definitive study, is ongoing [26] , the data presented so far are consistent with de-escalation of bone-targeting agents becoming a standard of care for patients with bone metastases from breast cancer.
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